Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a hold rating to a strong-buy rating in a report issued on Tuesday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $4.00 to $6.00 in a research note on Wednesday. Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. Piper Sandler began coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of “Buy” and an average price target of $11.63.

Compass Therapeutics Stock Down 24.6 %

Shares of NASDAQ:CMPX opened at $1.69 on Tuesday. The stock has a market cap of $233.70 million, a PE ratio of -4.57 and a beta of 1.19. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The business has a 50 day moving average of $2.81 and a 200-day moving average of $2.11.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CMPX. MPM Bioimpact LLC increased its holdings in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after purchasing an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics during the fourth quarter valued at about $11,293,000. Tang Capital Management LLC grew its holdings in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. Rock Springs Capital Management LP increased its stake in shares of Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after buying an additional 150,336 shares during the period. Finally, Blue Owl Capital Holdings LP raised its holdings in Compass Therapeutics by 2.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after buying an additional 75,000 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.